The Foundation for Neglected Disease Research (FNDR) and DevsHealth have joined forces to develop new antiviral agents targeting flaviviruses like dengue, Zika, and West Nile virus. These viruses cause millions of infections annually, mainly affecting low- and middle-income countries, with severe cases leading to life-threatening conditions. The collaboration aims to revolutionize flavivirus treatment by creating affordable, broad-spectrum drugs using cutting-edge AI/ML technologies.
The absence of effective drugs for flaviviruses presents a significant challenge, especially in regions with high disease burdens. By combining FNDR’s expertise in infectious disease research with DevsHealth’s AI-driven drug development platform, the collaboration seeks to accelerate the discovery of potent antiviral agents. DevsHealth will focus on computational studies and chemistry, while FNDR will handle laboratory experiments, paving the way for a comprehensive drug development process.
DevsHealth’s CEO, Alfons Nonell-Canals, emphasizes the social impact of the collaboration, highlighting the importance of leveraging technology to enhance healthcare accessibility, particularly in low- and middle-income countries. Dr. Shridhar Narayanan, FNDR’s CEO, underscores the synergy between AI/ML technologies and traditional drug discovery methods in fast-tracking the development of broad-spectrum antiviral drugs for mosquito-borne diseases, aligning with FNDR’s mission of tackling neglected infectious diseases.
FNDR, a not-for-profit organization established in 2014, has a robust track record in developing therapeutics for various infectious diseases, including tuberculosis, malaria, and COVID-19. With state-of-the-art research facilities in Bengaluru, India, FNDR adopts a One Health approach to address global health challenges, such as antimicrobial resistance and pandemic preparedness. DevsHealth, founded in July 2021, specializes in leveraging AI, real-world data, and molecular modeling to expedite the development of anti-infectious treatments, with a focus on reducing development risks and timelines.
The collaboration between FNDR and DevsHealth holds promise for addressing the urgent need for effective flavivirus treatments, particularly in regions with limited resources. By combining AI/ML technologies with traditional drug discovery methods, the partnership aims to accelerate the identification and development of affordable and accessible antiviral drugs. This collaborative effort signifies a step forward in combating mosquito-borne infections and underscores the potential of innovative technologies in revolutionizing global healthcare.
Takeaways:
– The partnership between FNDR and DevsHealth aims to develop affordable and broad-spectrum antiviral drugs for flaviviruses like dengue and Zika.
– By leveraging AI/ML technologies and traditional drug discovery methods, the collaboration seeks to accelerate the drug development process.
– FNDR’s expertise in infectious disease research, coupled with DevsHealth’s AI-driven platform, enables a comprehensive approach to tackling neglected infectious diseases.
– The collaboration highlights the importance of technology in enhancing healthcare accessibility, particularly in low- and middle-income countries.
Tags: clinical trials, biotech, pandemic preparedness
Read more on news.webindia123.com